Edwards Lifesciences (EW) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Edwards Lifesciences (EW) shares decline as growth disappoints investors
July 27, 2023 12:19 PM EDTShares of Edwards Lifesciences (NYSE: EW) declined after it reported second quarter results. Despite solid earnings per share and revenue, growth rates disappointed investors.
Edwards Lifesciences reported second quarter sales that were slightly above consensus at $1.53 billion. At $0.66, EPS topped consensus by a penny.
The company expects full year 2023 sales to be between $5.9 billion and $6.1 billion. For the year, the company expects transcatheter aortic... More
